Stock Analiz

Capricor Therapeutics, Inc. CAPR

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$9.53Market cap $554M
Open the interactive analysis →

Capricor Therapeutics, Inc. (CAPR) is a healthcare company listed in the US with a market value of about $554M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -60%.

About Capricor Therapeutics

Capricor Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $5M in 2014 to $22M in 2024, growth of about 16.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 89% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B2.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-23.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2395.9%
ROIC (5-yr avg.)-60.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$22M$25M$3M$244898$310250$1M$2M$3M$4M
Net income-$105M-$40M-$22M-$29M-$20M-$14M-$8M-$15M$2M-$19M
Free cash flow-$73M-$41M-$27M$3M-$18M-$11M-$7M-$14M-$14M-$15M
EPS (diluted)$-2.26$-1.15$-0.83$-1.18$-0.87$-0.88$-2.06$-5.20$0.90$-10.10
Net margin—-181.7%-88.5%-1137.4%-8175.9%-4401.9%-760.4%-908.9%91.2%-470.3%
ROIC-26.7%-22.9%-67.4%-135.1%-48.3%-37.9%-89.3%-262.3%-90.5%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $27.25, 186% above the current price; targets range from $10.50 to $54.00; the consensus rating is “Buy”; expected EPS is $-2.45 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Capricor Therapeutics pay a dividend?

Not currently.

Is Capricor Therapeutics a good stock to buy?

We do not give buy or sell advice. Capricor Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.